Cara Therapeutics (CARA) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CARA Hot Sheet
Join SI Premium – FREE
Cara Therapeutics (NASDAQ: CARA) reported Q2 EPS of ($0.48), $0.06 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $79 thousand versus the consensus estimate of $130 thousand.
For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Netflix gains after Ackman endorsement and AI feature launch
- VivoPower posts $6.8M revenue and $0.6M profit in Q1 FY2027
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
